High Tech Pharm Co Ltd
KOSDAQ:106190
Intrinsic Value
HIGH TECH PHARM Co., Ltd. engages in the manufacture and sale of raw materials for injectable antibiotic products. [ Read More ]
The intrinsic value of one High Tech Pharm Co Ltd stock under the Base Case scenario is hidden KRW. Compared to the current market price of 14 900 KRW, High Tech Pharm Co Ltd is hidden .
Valuation Backtest
High Tech Pharm Co Ltd
Run backtest to discover the historical profit from buying and selling High Tech Pharm Co Ltd stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
This note will be permanently deleted.
Balance Sheet Decomposition
High Tech Pharm Co Ltd
| Current Assets | 69.5B |
| Cash & Short-Term Investments | 14.8B |
| Receivables | 17.9B |
| Other Current Assets | 36.8B |
| Non-Current Assets | 77.6B |
| Long-Term Investments | 2.3B |
| PP&E | 74.2B |
| Other Non-Current Assets | 1.1B |
| Current Liabilities | 32.2B |
| Accounts Payable | 16.6B |
| Accrued Liabilities | 961.4m |
| Short-Term Debt | 11.7B |
| Other Current Liabilities | 3B |
| Non-Current Liabilities | 5.3B |
| Long-Term Debt | 5B |
| Other Non-Current Liabilities | 276.4m |
Earnings Waterfall
High Tech Pharm Co Ltd
|
Revenue
|
82.5B
KRW
|
|
Cost of Revenue
|
-65.4B
KRW
|
|
Gross Profit
|
17.2B
KRW
|
|
Operating Expenses
|
-2.9B
KRW
|
|
Operating Income
|
14.3B
KRW
|
|
Other Expenses
|
-2.7B
KRW
|
|
Net Income
|
11.6B
KRW
|
Free Cash Flow Analysis
High Tech Pharm Co Ltd
| KRW | |
| Free Cash Flow | KRW |
Profitability Score
Profitability Due Diligence
High Tech Pharm Co Ltd's profitability score is hidden . The higher the profitability score, the more profitable the company is.
Score
High Tech Pharm Co Ltd's profitability score is hidden . The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
High Tech Pharm Co Ltd's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Score
High Tech Pharm Co Ltd's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
High Tech Pharm Co Ltd
According to Wall Street analysts, the average 1-year price target for High Tech Pharm Co Ltd is 26 000 KRW .
Shareholder Return
Price
High Tech Pharm Co Ltd
| Average Annual Return | 1.23% |
| Standard Deviation of Annual Returns | 48.16% |
| Max Drawdown | -70% |
| Market Capitalization | 158.4B KRW |
| Shares Outstanding | 10 632 625 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
HIGH TECH PHARM Co., Ltd. engages in the manufacture and sale of raw materials for injectable antibiotic products. The company is headquartered in Chungju, Chungcheongbuk-Do and currently employs 99 full-time employees. The company went IPO on 2010-07-28. CO., LTD. is a Korea-based company mainly engaged in the manufacture of antibiotic pharmaceutical ingredients for injections. The firm's products include sterile imipenem, sterile cilastatin sodium, sterile blended imipenem and cilastatin sodium, injectable sterile meropenem, injectable sterile panipenem, faropenem and others. The firm distributes its products within domestic market and to overseas markets.
Contact
IPO
Employees
Officers
The intrinsic value of one High Tech Pharm Co Ltd stock under the Base Case scenario is hidden KRW.
Compared to the current market price of 14 900 KRW, High Tech Pharm Co Ltd is hidden .
You don't have any saved screeners yet
